Product Code: DMKC12571
The value of the stroke prevention in atrial fibrillation (SPAF) market is expected to grow rapidly as novel oral anticoagulant (NOAC) class molecules secure approvals of their antidotes and physician acceptance of these drugs rises.
This report addresses the following questions:
- Which patient subgroups and markets will have the largest impact on SPAF sales?
- How will the approval of antidotes affect uptake of the NOAC class?
- Will Savaysa's recent approval for SPAF have a significant effect on the market dynamics?
- What are the most commonly prescribed therapies for stroke prevention in both valvular and non-valvular atrial fibrillation patients?
- What are the most important factors influencing prescribing trends?
- How do prescribing trends correlate with current recommendations from clinical guidelines?
TABLE OF CONTENTS
FORECAST: STROKE PREVENTION IN ATRIAL FIBRILLATION
- 1. Executive Summary
- 2. Market Overview and Trends
- 3. Market Definition and Methodology
- 4. Eliquis (apixaban)
- 5. Pradaxa (dabigatran)
- 6. Savaysa (edoxaban)
- 7. Xarelto (rivaroxaban)
- 8. Primary Research Methodology
TREATMENT: STROKE PREVENTION IN ATRIAL FIBRILLATION
- 9. Executive Summary
- 10. Primary Research Methodology
- 11. Disease Definition and Diagnosis
- 12. Country Treatment Trees
- 13. Current Treatment Options
- 14. Prescribing Trends
EPIDEMIOLOGY: ATRIAL FIBRILLATION
- 15. Executive Summary
- 16. Disease Background
- 17. Sources and Methodology
- 18. Forecast
- 19. Epidemiologist Insight
- 20. Strengths and Limitations
MARKETED DRUGS: STROKE PREVENTION IN ATRIAL FIBRILLATION
- 21. Executive Summary
- 22. Product Overview
- 23. Product profile: Eliquis
- 24. Product profile: Pradaxa
- 25. Product profile: Savaysa
- 26. Product profile: Xarelto
PIPELINE: STROKE PREVENTION IN ATRIAL FIBRILLATION
- 27. Executive Summary
- 28. Pipeline Trends